trending Market Intelligence /marketintelligence/en/news-insights/trending/8t9-z9_yvdwmw7_phyxjoq2 content esgSubNav
In This List

Bristol-Myers' Opdivo, Yervoy combo meets goal in late-stage lung cancer study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Bristol-Myers' Opdivo, Yervoy combo meets goal in late-stage lung cancer study

Bristol-Myers Squibb Co. said a combination of its cancer treatments Opdivo and Yervoy in a first-line setting was better at containing the spread of tumor in patients with non-small cell lung cancer when compared to chemotherapy.

The combination met its co-primary endpoint of progression-free survival in an ongoing phase 3 study known as CheckMate -227.

The trial's data monitoring committee has recommended that the study continue based on an interim analysis of the number of patients whose tumors shrank.

More recently, the company said the combination showed durable clinical benefit in colon cancer patients enrolled in a phase 2 study.